A case of ROS1‐rearranged lung adenocarcinoma exhibiting pleural effusion caused by crizotinib

• Published in: Thoracic cancer Vol. 11; no. 7; pp. 2063 - 2066
• Main Authors: Tachi, Hiroaki, Nishino, Kengo, Nakaizumi, Taisuke, Kuramoto, Kenya, Shimizu, Kei, Yamamoto, Yusuke, Kobayashi, Keisuke, Ichimura, Hideo, Sakata, Akiko, Nawa, Takeshi
• Format: Journal Article
• Language: English
• Published: Melbourne John Wiley & Sons Australia, Ltd 01.07.2020; John Wiley & Sons, Inc; Wiley
• Subjects: Adenocarcinoma; Adenocarcinoma of Lung - drug therapy; Adenocarcinoma of Lung - genetics; Adenocarcinoma of Lung - pathology; Adult; Antineoplastic Agents - adverse effects; Biopsy; Blood tests; Case Report; Case Reports; Cellular biology; Complete response; Crizotinib; Crizotinib - adverse effects; Drug withdrawal; Drugs; Female; Gene Rearrangement; Health aspects; Humans; Kinases; lung adenocarcinoma; Lung cancer; Lung cancer, Non-small cell; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - pathology; Lungs; Lymphatic system; Lymphocytes; Metastasis; Pleural effusion; Pleural Effusion - chemically induced; Pleural Effusion - pathology; Pleural effusions; Prognosis; Protein-Tyrosine Kinases - genetics; Proto-Oncogene Proteins - genetics; Response rates; ROS1 rearrangement; Targeted cancer therapy; ROS1 rearrangement; crizotinib; pleural effusion; Complete response; lung adenocarcinoma
• ISSN: 1759-7706; 1759-7714; 1759-7714
• DOI: 10.1111/1759-7714.13496

Reports of crizotinib‐induced pleural effusion in non‐small cell lung cancer (NSCLC) are limited. A 35‐year‐old Japanese woman was diagnosed with ROS1‐rearranged lung adenocarcinoma (primary left lower lobe, cT4N3M1c). Crizotinib was administered as first‐line therapy, and the primary and mediastinal hilar lymph node metastases rapidly shrank. On the fourth day of treatment, chest X‐ray demonstrated contralateral pleural effusion. On the 41st day of treatment, crizotinib was discontinued because of grade 3 neutropenia. Examination including surgical thoracoscopy did not reveal causative findings, and the continued cessation of drug administration enabled the right pleural effusion to decrease gradually and disappear, suggesting that this event was a side effect of crizotinib. The disease did not progress even though the drug was withdrawn for more than one year. In conclusion, crizotinib was considered to cause pleural effusion as an adverse event in a case of ROS1‐rearranged lung adenocarcinoma with a complete response.